MedTrace Logo

Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)

NCT05447650 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2025-06-24

No results posted yet for this study

Summary

Evaluate the safety and efficacy of transpalpebral microcurrent stimulation (MCS) therapy for patients with nonexudative (dry) age-related macular degeneration (AMD).

Conditions

Interventions

DEVICE

i-Lumen(TM) AMD

Transpalpebral microcrurrent stimulation

DEVICE

i-Lumen(TM) AMD Sham

Transpalpebral sham stimulation

Sponsors & Collaborators

  • i-Lumen Scientific, Inc.

    lead INDUSTRY

Principal Investigators

  • Meredith Mundy · i-Lumen Scientific, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-12
Primary Completion
2025-06-15
Completion
2025-06-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05447650 on ClinicalTrials.gov